The target has been on a downward slide for years, with the shares falling about 80% since the medication, Andexxa, was approved in 2018. The deal means the $22 billion biotech snaps up a promising drug to reverse anticoagulants. NEW YORK, May 5 (Reuters Breakingviews) - Alexion Pharmaceuticals is either buying Portola Pharmaceuticals on the cheap at $1.4 billion, or paying a whopping premium – it all depends on your starting date. ![]() (The author is a Reuters Breakingviews columnist.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |